Frontlight ResearchEarly access
Not yet recruitingPhase 2
A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Bacteria
Key facts
- Who runs it
- Pfizer Inc.
- Where
- Bulgaria, Greece, Hungary, Italy, Slovakia, and Spain20 sites in 6 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 18 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 3 Aug 2028
- Type of study
- Interventional
- Record updated
- 15 September 2026
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Hospitalized with age from birth <9 months, including preterm birth
- Part A: Receiving IV antibiotics for treatment of suspected or confirmed bacterial infection, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis
- Part B: Suspected or confirmed gram-negative bacterial infection requiring IV antibiotics, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis
Who cannot take part
- Received any other investigational medicinal product within the longer of 30 days or 5 half-lives before enrollment
- Part B Only: Received >24 hours of systemic antibiotic treatment for gram-negative organisms at time of enrollment, unless documented treatment failure or lack of improvement in at least one objective sign or symptom of infection after ≥48 hours of antibiotics
- Any medical or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study
- Severe renal impairment or known significant renal disease, as evidenced by elevated serum creatinine at screening, or urinary output <0.5 mL/kg/h for 6 consecutive hours or requirement for dialysis
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluate the PK of ATM-AVI for the treatment of gram-negative bacterial infections including complicated urinary tract infection (cUTI), complicated intraabdominal infection (cIAI), hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP), blood stream infection (BSI), or sepsis in hospitalized neonates and infants from birth to <9 month of age.
Read full original descriptionShow less
Evaluate the safety and tolerability of ATM-AVI in hospitalized neonates and infants from birth to <9 months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- C3601010: A Phase 2A, 2-Part, Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam ± Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment
- Record updated
- 15 September 2026